Circulating tumor DNA (ctDNA) mutations may predict treatment response in extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib and temozolomide (TMZ).

Authors

null

Matthew C Mulroy

UCLA Medical Center, Los Angeles, CA

Matthew C Mulroy , Amy Lauren Cummings , Melody A. Mendenhall , David E. Kanamori , Andrew V. Nguyen , David Dae-Young Kim , William E. Lawler , Tirrell T. Johnson , Jennifer Tseng , Sunil Babu , Andrew Bennett Brown , Shaker R. Dakhil , Sidharth Anand , Zev A. Wainberg , Dennis J. Slamon , Edward B. Garon , Jonathan Wade Goldman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03672773

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 8564)

DOI

10.1200/JCO.2021.39.15_suppl.8564

Abstract #

8564

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Annual Meeting

HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).

HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).

First Author: June Evelyn Jeon

Poster

2023 ASCO Annual Meeting

The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?

The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?

First Author: Muhammad Danyal Ahsan